Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice - PubMed (original) (raw)
Stromelysin-1 (MMP-3) is critical for intracranial bleeding after t-PA treatment of stroke in mice
Y Suzuki et al. J Thromb Haemost. 2007 Aug.
Free article
Abstract
Background: Tissue-type plasminogen activator (t-PA) is approved for treatment of ischemic stroke patients, but it may increase the risk of intracranial bleeding (ICB). Matrix metalloproteinases (MMPs), which can be activated through the plasminogen/plasmin system, may contribute to ICB after ischemic stroke.
Objectives: To explore the contribution of plasminogen, MMP-3 and MMP-9 to ICB associated with t-PA treatment after ischemic stroke.
Methods: Using a thrombotic middle cerebral artery occlusion (MCA-O) model, ICB was studied in mice with genetic deficiencies of plasminogen (Plg(-/-)), stromelysin-1 (MMP-3(-/-)), or gelatinase B (MMP-9(-/-)) and their corresponding wild-type (WT) littermates. The induction of MMP-3 and MMP-9 was also studied in C57BL/6 WT mice.
Results: ICB induced by t-PA (10 mg kg(-1)) was significantly less than WT in Plg(-/-) (P < 0.05) and MMP-3(-/-) (P < 0.05) but not in MMP-9(-/-) mice. Furthermore, administration of the broad-spectrum MMP inhibitor GM6001 after t-PA treatment reduced ICB significantly (P < 0.05) in MMP-3(+/+) mice, but had no effect on MMP-3(-/-) mice. MMP-3 expression was significantly enhanced at the ischemic hemisphere; with placebo treatment, it was expressed only in neurons, whereas it was up-regulated in endothelial cells with t-PA treatment. Although MMP-9 expression was also significantly enhanced at the ischemic brain, the amount and the distribution were comparable in mice with and without t-PA treatment.
Conclusions: Our data with gene-deficient mice thus suggest that plasminogen and MMP-3 are relatively more important than MMP-9 for the increased ICB induced by t-PA treatment of ischemic stroke.
Similar articles
- Tissue-type plasminogen activator (t-PA) induces stromelysin-1 (MMP-3) in endothelial cells through activation of lipoprotein receptor-related protein.
Suzuki Y, Nagai N, Yamakawa K, Kawakami J, Lijnen HR, Umemura K. Suzuki Y, et al. Blood. 2009 Oct 8;114(15):3352-8. doi: 10.1182/blood-2009-02-203919. Epub 2009 Jul 16. Blood. 2009. PMID: 19608750 - Role of tissue-type plasminogen activator in ischemic stroke.
Suzuki Y. Suzuki Y. J Pharmacol Sci. 2010;113(3):203-7. doi: 10.1254/jphs.10r01cp. Epub 2010 Jun 29. J Pharmacol Sci. 2010. PMID: 20595786 Review. - Differences in Acute Expression of Matrix Metalloproteinases-9, 3, and 2 Related to the Duration of Brain Ischemia and Tissue Plasminogen Activator Treatment in Experimental Stroke.
Wang D, Saleem S, Sullivan RD, Zhao T, Reed GL. Wang D, et al. Int J Mol Sci. 2024 Aug 30;25(17):9442. doi: 10.3390/ijms25179442. Int J Mol Sci. 2024. PMID: 39273389 Free PMC article. - Baicalin Attenuates Blood-Brain Barrier Disruption and Hemorrhagic Transformation and Improves Neurological Outcome in Ischemic Stroke Rats with Delayed t-PA Treatment: Involvement of ONOO--MMP-9 Pathway.
Chen H, Guan B, Chen X, Chen X, Li C, Qiu J, Yang D, Liu KJ, Qi S, Shen J. Chen H, et al. Transl Stroke Res. 2018 Oct;9(5):515-529. doi: 10.1007/s12975-017-0598-3. Epub 2017 Dec 23. Transl Stroke Res. 2018. PMID: 29275501
Cited by
- Matrix metalloproteinase-2 or -9 deletions protect against hemorrhagic transformation during early stage of cerebral ischemia and reperfusion.
Suofu Y, Clark JF, Broderick JP, Kurosawa Y, Wagner KR, Lu A. Suofu Y, et al. Neuroscience. 2012 Jun 14;212:180-9. doi: 10.1016/j.neuroscience.2012.03.036. Epub 2012 Apr 19. Neuroscience. 2012. PMID: 22521821 Free PMC article. - Candesartan reduces the hemorrhage associated with delayed tissue plasminogen activator treatment in rat embolic stroke.
Ishrat T, Pillai B, Ergul A, Hafez S, Fagan SC. Ishrat T, et al. Neurochem Res. 2013 Dec;38(12):2668-77. doi: 10.1007/s11064-013-1185-y. Epub 2013 Nov 6. Neurochem Res. 2013. PMID: 24194350 Free PMC article. - A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia.
Suzuki Y, Nagai N, Umemura K. Suzuki Y, et al. Front Cell Neurosci. 2016 Jan 25;10:2. doi: 10.3389/fncel.2016.00002. eCollection 2016. Front Cell Neurosci. 2016. PMID: 26834557 Free PMC article. Review. - Protective Effects of Autologous Bone Marrow Mononuclear Cells After Administering t-PA in an Embolic Stroke Model.
Yang B, Li W, Satani N, Nghiem DM, Xi X, Aronowski J, Savitz SI. Yang B, et al. Transl Stroke Res. 2018 Apr;9(2):135-145. doi: 10.1007/s12975-017-0563-1. Epub 2017 Aug 23. Transl Stroke Res. 2018. PMID: 28836238 - The role of oxidative stress in blood-brain barrier disruption during ischemic stroke: Antioxidants in clinical trials.
Lochhead JJ, Ronaldson PT, Davis TP. Lochhead JJ, et al. Biochem Pharmacol. 2024 Oct;228:116186. doi: 10.1016/j.bcp.2024.116186. Epub 2024 Mar 30. Biochem Pharmacol. 2024. PMID: 38561092 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Miscellaneous